<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880565</url>
  </required_header>
  <id_info>
    <org_study_id>CV-2018-27226</org_study_id>
    <nct_id>NCT03880565</nct_id>
  </id_info>
  <brief_title>Advanced Reperfusion Strategies for Refractory Cardiac Arrest</brief_title>
  <acronym>ARREST</acronym>
  <official_title>Advanced REperfusion STrategies for Refractory Cardiac Arrest (The ARREST Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, single center (Under the Center for Resuscitation Medicine at the&#xD;
      University of Minnesota Medical School), partially blinded, prospective, intention to treat,&#xD;
      safety and efficacy clinical trial, randomizing adult patients (18-75 years old) with&#xD;
      refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/VT) out-of hospital&#xD;
      cardiac arrest (OHCA) who are transferred by emergency medical services (EMS) with ongoing&#xD;
      mechanical cardiopulmonary resuscitation (CPR) or who are resuscitated to receive one of the&#xD;
      2 local standards of care practiced in our community: 1) Early Extracorporeal Membrane&#xD;
      Oxygenation (ECMO) Facilitated Resuscitation or 2) Standard Advanced Cardiac Life Support&#xD;
      (ACLS) Resuscitation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy&#xD;
  </why_stopped>
  <start_date type="Actual">August 9, 2019</start_date>
  <completion_date type="Actual">October 9, 2020</completion_date>
  <primary_completion_date type="Actual">October 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>1 week</time_frame>
    <description>Number of participants who expire during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) Score</measure>
    <time_frame>1 week, 3 months, 6 months</time_frame>
    <description>mRS scale ranges from 0 (no residual symptoms) to 6 (dead) with 7 (unable to contact patient/caregiver) and 8 (mRS not performed). Scores of 3 (the patient has moderate disability), 2 (the patient has slight disability), 1 (the patient has no significant disability), and 0 indicate favorable outcome. Outcome is reported as the number of participants survival to hospital discharge with an mRS score of 3 or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Performance Categories (CPC) Scale</measure>
    <time_frame>1 week, 3 months, 6 months</time_frame>
    <description>CPC scale ranges from 1 (good cerebral performance) to 5 (brain death). CPC scores of 2 (moderate cerebral disability) and 1 indicate functional status. Higher scores on the scale indicate worse cerebral performance. Outcome is reported as the mean score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment cost</measure>
    <time_frame>6 months</time_frame>
    <description>Outcome is reported as the mean treatment cost in dollars.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cardiac Arrest</condition>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <condition>Ventricular Fibrillation</condition>
  <condition>Pulseless Ventricular Tachycardia</condition>
  <condition>Out-Of-Hospital Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>ECMO Facilitated Resuscitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation: ECMO is initiated expeditiously, regardless of whether return of spontaneous circulation (ROSC) has been achieved and with on-going mechanical CPR, if required, followed by coronary angiography and percutaneous coronary intervention (PCI) when appropriate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard ACLS Resuscitation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard Advanced Cardiac Life Support (ACLS) Resuscitation: Patients with refractory VF/VT OHCA will be treated with ACLS resuscitation for at least 15 minutes after arrival in the emergency department (ED), or up to 60 minutes from 911 call, after which the physician (MD) can continue resuscitation efforts until ROSC is achieved or futility has been reached based on their clinical judgment. If the patient has not achieved ROSC during the times mentioned above, the ED MD can declare death when he or she believes that ACLS is futile. If ROSC is present upon arrival or has been achieved anytime during resuscitation in the ED, the patient will be taken to the cardiac catheterization laboratory (CCL) for coronary angiography and PCI and potential VA ECMO or other circulatory support device initiation, as clinically indicated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation</intervention_name>
    <description>Early use of ECMO</description>
    <arm_group_label>ECMO Facilitated Resuscitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Advanced Cardiac Life Support (ACLS) Resuscitation</intervention_name>
    <description>Standard life support resuscitation</description>
    <arm_group_label>Standard ACLS Resuscitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (presumed or known to be aged 18-75 years, inclusive),&#xD;
&#xD;
          -  An initial documented OHCA rhythm of VF/VT,&#xD;
&#xD;
          -  No ROSC following 3 defibrillation shocks,&#xD;
&#xD;
          -  Body morphology able to accommodate a Lund University Cardiac Arrest System (LUCASâ„¢)&#xD;
             automated CPR device, and&#xD;
&#xD;
          -  Estimated transfer time from the scene to the ED or CCL of &lt; 30 minutes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old or &gt; 75 years old;&#xD;
&#xD;
          -  Non-shockable initial OHCA rhythm (pulseless electrical activity [PEA] or asystole);&#xD;
&#xD;
          -  Valid do-not-attempt-resuscitation orders (DNAR);&#xD;
&#xD;
          -  Blunt, penetrating, or burn-related injury, drowning, electrocution or known overdose;&#xD;
&#xD;
          -  Known prisoners;&#xD;
&#xD;
          -  Known pregnancy;&#xD;
&#xD;
          -  Nursing home residents;&#xD;
&#xD;
          -  Unavailability of the cardiac catheterization laboratory.&#xD;
&#xD;
          -  Severe concomitant illness that drastically shortens life expectancy or increases risk&#xD;
             of the procedure;&#xD;
&#xD;
          -  Absolute contraindications to emergent coronary angiography including known&#xD;
             anaphylactic reaction to angiographic contrast media and/or active gastrointestinal or&#xD;
             internal bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Demetris Yannopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Aufderheide, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Medical Center, Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced reperfusion</keyword>
  <keyword>mechanical cardiopulmonary resuscitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03880565/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>September 20, 2021</submitted>
    <returned>October 19, 2021</returned>
    <submitted>October 25, 2021</submitted>
    <returned>November 18, 2021</returned>
    <submitted>November 18, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

